Helixbind, Inc.
Boxborough, MA Doing business as Helixbind Inc.
- UEI
- C37HLWKKAH69
- CAGE
- 6TH55
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1300 Massachusetts Ave #103, Boxborough, MA 01719, USA
- Website
- helixbind.com
- Founded
- 2013
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Helixbind, Inc.
Helixbind, Inc. is a for-profit corporate entity registered in SAM.gov since November 2012, specializing in advanced molecular diagnostic technologies with a primary focus on developing innovative, rapid diagnostic systems for infectious diseases. The company has positioned itself as a technology developer creating cutting-edge diagnostic platforms that enable faster, more accurate identification of complex medical conditions, particularly bloodstream infections, Lyme disease, and other infectious diseases. Their core technology, the RAPID (Resistance and Pathogen Identification) platform, represents a breakthrough approach to diagnostics that allows for direct pathogen detection from clinical specimens without traditional culture methods.
Through multiple federal grant awards from the National Institute of Allergy and Infectious Diseases (NIAID), Helixbind has developed several specialized diagnostic tests targeting critical medical challenges. These include RAPID/BSI for bloodstream infection identification, which can detect 20-21 bacterial and fungal pathogens within approximately 3-4 hours, RAPID/LD for Lyme disease detection, RAPID/IE for endocarditis identification, and RAPID/NEO for neonatal sepsis detection. Each of these diagnostic tools is designed to provide species-level identification with high sensitivity (>92%), enable precise antimicrobial selection, and overcome limitations of traditional blood culture methods. The grant awards, typically ranging from $1-1.2 million, support product development, verification, validation, and preparation for FDA regulatory clearance, with project periods spanning approximately 3 years and focusing on commercialization of these breakthrough diagnostic technologies.
Quick answers
What is Helixbind, Inc.'s UEI?
Helixbind, Inc.'s Unique Entity ID (UEI) in SAM.gov is C37HLWKKAH69.
What is Helixbind, Inc.'s CAGE code?
Helixbind, Inc.'s CAGE code is 6TH55.
What is Helixbind, Inc.'s primary NAICS code?
Helixbind, Inc.'s primary NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing).
Where is Helixbind, Inc. located?
Helixbind, Inc.'s physical address in SAM.gov is 1300 Massachusetts Ave #103, Boxborough, MA 01719, USA.
Is Helixbind, Inc. registered in SAM.gov?
Yes. Helixbind, Inc.'s SAM.gov registration is active through May 13, 2027.
What is Helixbind, Inc.'s most recent federal award?
Helixbind, Inc.'s most recent federal grant award is Automated system for the direct from blood characterization of bloodstream infections - project summary septicemia, a… (R44AI197309), from National Institute of Allergy and Infectious Diseases, on July 16, 2026.
On GovTribe
See Helixbind, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors